South Korea's Daewoo Shipbuilding & Marine Engineering Co. suffered a net loss of 29.2 billion won in the third quarter despite robust operating profit due to a 50 billion won loan to a subsidiary written off in its books as a loss.
The net loss shrank from 296.4 billion last year.
Operating profit came to 33.6 billion won in the third period, a turnaround from an operating loss of 256.3 billion won, while sales fell 26 percent to 1.44 trillion won.
In the first nine months of the year, sales came in at 5.37 trillion won and operating profit was 386 billion won. Net profit stood at 264.8 billion won.
The company added that its debt-to-equity ratio decreased to 161.4 percent in the third quarter from 200.3 percent at the end of 2019.
Weak orders due to the pandemic decreased its order backlogs.


Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10%
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 



